Puma Biotech (PBYI), Pierre Fabre Amend NERLYNX® License Agreement to Include Greater China
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
Puma Biotech (PBYI) Tops Q4 EPS by 15c
February 25, 2021 5:30 PM ESTPuma Biotech (NASDAQ: PBYI) reported Q4 EPS of ($0.14), $0.15 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $52.6 million versus the consensus estimate of $52.79 million.
During the fourth quarter of 2020 Puma continued to be negatively impacted by the challenges of COVID-19; however, we were pleased to be able to achieve NERLYNX revenues that were within the previously stated guidance, said Alan H. Auerbach, Chairman, Chief Executive Officer and President of Puma. Our year concluded with a number of positive clinical milestones for the Company, including the publication of ExteNET data in Clinical... More
